FINWIRES · TerminalLIVE
FINWIRES

Clinuvel Pharmaceuticals Identifies High-Potential Dose Formulations for Injectable Peptide Platform

By

Clinuvel Pharmaceuticals (ASX:CUV) said it identified flexible liquid dose formulations that have shown the most potential for further development as part of its VLRX-L injectable peptide formulation platform, according to a Wednesday filing with the Australian bourse.

Optimization is now underway at the company's research and development center in Singapore, with further pre-clinical studies scheduled for early in the first quarter of 2027, pending final results, per the filing.

In the latest pre-clinical study with four candidate formulations, one candidate "demonstrated a superior release profile over the targeted peptide delivery window, with lower peak plasma levels and drug detected over the delivery period," the company said.

Related Articles

Asia

Guolian Securities to Repurchase Up to 200 Million Yuan of Shares

Guolian Securities (SHA:601456, HKG:1456) is looking to buy back between 100 million yuan and 200 million yuan of shares, according to a Tuesday filing with the Shanghai bourse.The securities company could buy between 7.7 million and 15.4 million shares at 13 yuan apiece.The share repurchase will help protect the company's value and shareholder rights, Guolian said in its filing.

HKG:1456SHA:601456
Asia

CP Axtra's Profit Declines in Q2

CP Axtra (BKK:CPAXT) reported a profit attributable to owners of 1.87 billion baht in the second quarter, down from 2.29 billion baht a year earlier.Earnings per share were 0.18 baht, compared with 0.22 baht in the year-ago period, according to an Aug. 7 Thailand Exchange filing.Total revenue rose to 132.3 billion baht from 129.1 billion baht previously.

BKK:CPAXT
Asia

Update: Austal Gets Up to $1.2 Billion Offer for US Operations From Hanwha Unit; Shares Up 19%

(Updates to add stock movement in the headline and the last paragraph)Australian shipbuilder Austal (ASX:ASB) received a non-binding, conditional proposal from a unit of South Korea's Hanwha Group to acquire its U.S. operations for an indicative enterprise value of up to $1.20 billion.Hanwha Defence USA has offered $1.05 billion to $1.20 billion for the relevant Austal USA entities and operations, according to a Tuesday press release.The proposed deal would cover 100% of the relevant Austal US entities but exclude Austal's publicly traded shares and its core Australasia operations in Australia, the Philippines, and Vietnam.The offer is subject to due diligence, regulatory approvals, and agreement on definitive transaction terms.Austal's board has approved a four-week due diligence period for Hanwha to review the US business and engage with key government and other counterparties.The proposal does not include a financing condition, the statement said.Austal's shares jumped around 19% in recent Tuesday trade.

ASX:ASB
Clinuvel Pharmaceuticals Identifies High-Potential Dose Formulations for Injectable Peptide Platform | FINWIRES